Fulltext

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial†

Tardif, Jean-Claude ; Ballantyne, Christie M. ; Barter, Philip ; Dasseux, Jean-Louis ; Fayad, Zahi A. ; Guertin, Marie-Claude ; Kastelein, John J. P. ; Keyserling, Constance ; Klepp, Heather ; Koenig, Wolfgang ; L'Allier, Philippe L. ; Lespérance, Jacques ; Lüscher, Thomas F. ; Paolini, John F. ; Tawakol, Ahmed ; Waters, David D. ; Pfeffer, M. ; Brown, V. ; Rouleau, J. ; Watkins, P. ; Wei, L.J. ; Gosselin, G. ; Chayer, C. ; Lanthier, S. ; Pelletier, G.B. ; Racine, N. ; Agarwal, H. ; Brilakis, E. ; Cannon, L. ; Carrié, D. ; Corbelli, J. ; Coste, P. ; de Winter, R. ; Diaz, A. ; Eisenberg, S. ; Ennis, B. ; Fajadet, J. ; Fam, N. ; Fortuin, D. ; Gessler, C. ; Grines, C. ; Guerra, D. ; Gum, H. ; Haldis, T. ; Heestermans, T. ; Herrman, J.P. ; Huynh, T. ; Kedhi, E. ; Koren, M. ; Kouz, S. ; Krolick, M. ; Kumkumian, G. ; Lavi, S. ; Li, R.J. ; Masud, ARZ ; McAlhany, C. ; McGrew, F.A. ; O'Shaughnessy, C. ; Oude Ophuis, A.J.M. ; Parr, K. ; Penny, W. ; Pesant, Y. ; Post, H. ; Robinson, S. ; Rodes-Cabau, J. ; Roy, A. ; Schulman, S. ; Spence, F. ; Stouffer, G. ; Stys, T. ; Sussex, B. ; Tahirkheli, N. ; Tardif, J-C ; Grégoire, J. ; ten Berg, J. ; van Boven, A.J. ; von Birgelen, C. ; Weinstein, D. ; Pfeffer, M. ; Brown, V. ; Rouleau, J. ; Watkins, P. ; Wei, L.J. ; Gosselin, G. ; Chayer, C. ; Lanthier, S. ; Pelletier, G.B. ; Racine, N. ; Agarwal, H. ; Brilakis, E. ; Cannon, L. ; Carrié, D. ; Corbelli, J. ; Coste, P. ; de Winter, R. ; Diaz, A. ; Eisenberg, S. ; Ennis, B. ; Fajadet, J. ; Fam, N. ; Fortuin, D. ; Gessler, C. ; Grines, C. ; Guerra, D. ; Gum, H. ; Haldis, T. ; Heestermans, T. ; Herrman, J.P. ; Huynh, T. ; Kedhi, E. ; Koren, M. ; Kouz, S. ; Krolick, M. ; Kumkumian, G. ; Lavi, S. ; Li, R.J. ; Masud, ARZ ; McAlhany, C. ; McGrew, F.A. ; O'Shaughnessy, C. ; Oude Ophuis, A.J.M. ; Parr, K. ; Penny, W. ; Pesant, Y. ; Post, H. ; Robinson, S. ; Rodes-Cabau, J. ; Roy, A. ; Schulman, S. ; Spence, F. ; Stouffer, G. ; Stys, T. ; Sussex, B. ; Tahirkheli, N. ; Tardif, J-C ; Grégoire, J. ; ten Berg, J. ; van Boven, A.J. ; von Birgelen, C. ; Weinstein, D.

In: European Heart Journal, 2014, vol. 35, no. 46, p. 3277-3286

Ajouter à la liste personnelle
    Titre
    • Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial†
    Auteur
    • Tardif, Jean-Claude. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), Université de Montréal, 5000 Belanger Street, Montreal, Canada H1T 1C8
    • Ballantyne, Christie M.. Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX, USA
    • Barter, Philip. Centre for Vascular Research, University of New South Wales, Sydney, Australia
    • Dasseux, Jean-Louis. Cerenis Therapeutics Holding, Labège, France
    • Fayad, Zahi A.. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, USA
    • Guertin, Marie-Claude. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), Université de Montréal, 5000 Belanger Street, Montreal, Canada H1T 1C8
    • Kastelein, John J. P.. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Keyserling, Constance. Cerenis Therapeutics Holding, Labège, France
    • Klepp, Heather. Cerenis Therapeutics Holding, Labège, France
    • Koenig, Wolfgang. Department of Internal Medicine II-Cardiology, Ulm University Medical Center, Ulm, Germany
    • L'Allier, Philippe L.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), Université de Montréal, 5000 Belanger Street, Montreal, Canada H1T 1C8
    • Lespérance, Jacques. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), Université de Montréal, 5000 Belanger Street, Montreal, Canada H1T 1C8
    • Lüscher, Thomas F.. Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
    • Paolini, John F.. Cerenis Therapeutics Holding, Labège, France
    • Tawakol, Ahmed. Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
    • Waters, David D.. University of California, San Francisco, CA, USA
    • Pfeffer, M.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Brown, V.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Rouleau, J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Watkins, P.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Wei, L.J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Gosselin, G.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Chayer, C.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Lanthier, S.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Pelletier, G.B.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Racine, N.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Agarwal, H.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Brilakis, E.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Cannon, L.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Carrié, D.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Corbelli, J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Coste, P.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • de Winter, R.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Diaz, A.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Eisenberg, S.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Ennis, B.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Fajadet, J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Fam, N.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Fortuin, D.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Gessler, C.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Grines, C.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Guerra, D.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Gum, H.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Haldis, T.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Heestermans, T.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Herrman, J.P.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Huynh, T.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Kedhi, E.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Koren, M.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Kouz, S.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Krolick, M.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Kumkumian, G.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Lavi, S.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Li, R.J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Masud, ARZ. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • McAlhany, C.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • McGrew, F.A.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • O'Shaughnessy, C.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Oude Ophuis, A.J.M.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Parr, K.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Penny, W.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Pesant, Y.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Post, H.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Robinson, S.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Rodes-Cabau, J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Roy, A.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Schulman, S.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Spence, F.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Stouffer, G.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Stys, T.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Sussex, B.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Tahirkheli, N.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Tardif, J-C. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Grégoire, J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • ten Berg, J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • van Boven, A.J.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • von Birgelen, C.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Weinstein, D.. Montreal Heart Institute and Montreal Heart Institute Coordinating Center (MHICC), 5000 Belanger Street, Montreal, H1T 1C8, Houston, TX, Centre for Vascular Research, Sydney, Cerenis Therapeutics Holding, Labège, Translational and Molecular Imaging Institute, New York, Department of Vascular Medicine, Amsterdam, Department of Internal Medicine II-Cardiology, Ulm, Cardiology, Zurich, Boston, MA, San Francisco, CA, Canada, USA, Australia, France, USA, The Netherlands, Germany, Switzerland, USA, USA
    • Pfeffer, M.
    • Brown, V.
    • Rouleau, J.
    • Watkins, P.
    • Wei, L.J.
    • Gosselin, G.
    • Chayer, C.
    • Lanthier, S.
    • Pelletier, G.B.
    • Racine, N.
    • Agarwal, H.
    • Brilakis, E.
    • Cannon, L.
    • Carrié, D.
    • Corbelli, J.
    • Coste, P.
    • de Winter, R.
    • Diaz, A.
    • Eisenberg, S.
    • Ennis, B.
    • Fajadet, J.
    • Fam, N.
    • Fortuin, D.
    • Gessler, C.
    • Grines, C.
    • Guerra, D.
    • Gum, H.
    • Haldis, T.
    • Heestermans, T.
    • Herrman, J.P.
    • Huynh, T.
    • Kedhi, E.
    • Koren, M.
    • Kouz, S.
    • Krolick, M.
    • Kumkumian, G.
    • Lavi, S.
    • Li, R.J.
    • Masud, ARZ
    • McAlhany, C.
    • McGrew, F.A.
    • O'Shaughnessy, C.
    • Oude Ophuis, A.J.M.
    • Parr, K.
    • Penny, W.
    • Pesant, Y.
    • Post, H.
    • Robinson, S.
    • Rodes-Cabau, J.
    • Roy, A.
    • Schulman, S.
    • Spence, F.
    • Stouffer, G.
    • Stys, T.
    • Sussex, B.
    • Tahirkheli, N.
    • Tardif, J-C
    • Grégoire, J.
    • ten Berg, J.
    • van Boven, A.J.
    • von Birgelen, C.
    • Weinstein, D.
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • European Heart Journal, 2014, vol. 35, no. 46, p. 3277-3286. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:303419
    Summary
    Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. Objective To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). Design and setting A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion. Patients Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively. Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001. Main outcome measures The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints. Results The nominal change in the total atheroma volume (adjusted means) was −2.71, −3.13, −1.50, and −3.05 mm3 with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, −0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was −0.022, −0.036, −0.022, and −0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was −0.51, 2.65, 0.71, and −0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups. Conclusion CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001&rank=2; Trial registration number: NCT01201837